Measurement of Potential Biomarkers Predicting Erlotinib Response
- To evaluate whether serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin can
be utilized as biomarkers to predict response in patients with non-small cell lung
cancer treated with erlotinib hydrochloride.
OUTLINE: Serum samples are analyzed for NGAL, MMP-9, NGAL/MMP-9, and soluble E-cadherin by
ELISA and Luminex assays.
Baseline serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin levels as predictors of erlotinib hydrochloride response
Steven M. Dubinett, MD
Jonsson Comprehensive Cancer Center